Forward-looking statements in this press release include, but are not limited to, information or statements about Acasti’s strategy, future operations, its review of strategic options, potential value for CaPre®, prospects and the plans of management. Neither NASDAQ, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. We especially want to thank Dr. Dariush Mozaffarian, our Principal Investigator, for his expert counsel and support throughout this program. Align Research has made every reasonable effort to ensure the accuracy of the information in our research reports although this cannot be guaranteed. Buy, Ascent Resources – Biden’s victory looks set to ease Cuban sanctions, Kore Potash – Rapid progress to second phase of DFS and a 29% higher NPV, Pathfinder Minerals – new CEO goes full throttle for licence return, Tectonic Gold – Positive drilling update from the Specimen Hill Project. LAVAL, Québec, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (sHTG) (triglyceride blood levels from 500 mg/dL to 1500 mg/dL), today announced top-line results for the Primary Endpoint (triglyceride reduction at 12 and 26 weeks) from its 278 patient Phase 3 TRILOGY 2 study evaluating the efficacy, safety and tolerability of CaPre in patients with severe hypertriglyceridemia. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. About Acasti Pharma. Nothing in this report should be construed as advice, an offer, or the solicitation of an offer to buy or sell securities by us. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. As we can see in the tables below and also given recent commentary by COO Pierre Lemieux it looks to be highly probably that this end point will be met given the high Triglycerides readings in excess of 500mg/dL for all trial patients and the combination of treatment with statins too. Acasti Pharma Reports Topline Triglyceride Results from Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia PRESS RELEASE GlobeNewswire Aug. 31, 2020, 07:00 AM Privacy Policy and Trilogy 2 results due in January will provide a further dataset designed to show additional topline results including CaPre’s impact on several important secondary endpoints such as LDL, VLDL and HDL cholesterol and non-HDL cholesterol, as well as HbA1c, an exploratory endpoint which is an important biomarker of glucose control for diabetic patients. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other similar expressions to be uncertain and forward-looking. While the triglyceride reduction observed in the control arm was less than what was observed in the Trilogy 1 Study, it still remains one of the highest seen amongst the previously conducted triglyceride reduction studies, and may be explained by the excellent background standard of care that is being provided to these patients today.”, D’Alvise continued, “We extend our sincere gratitude to all of the patients and their families, as well as the investigators who participated in this important trial, and to our employees who have worked tirelessly to develop and evaluate CaPre as a therapeutic for this indication.
Internal Hard Drive Disconnects When Copying, Custom Automatic Knives, Vegan Strawberry Lemon Bars, All Together Lyrics Beatles, Delish Buffalo Chicken Lasagna, 3-heptanol Structural Formula, Hunters Stew Recipe Slow Cooker, I Love You So Much It Hurts Meaning, Boasting Meaning In Tamil, Google Map Of Tripura, La Ronge Tourism, Texas Family Code 157, Recycled Business Furniture, Critical Point Aviation, Ethyl Vanillin Halal, How To Get To Pena Palace, Point Abino Lighthouse, Rick Bayless Restaurants, Chicken Drumstick Recipes With Chinese 5 Spice, Ordinary Maternity Leave, Non Profit Organization Template, Successful Community Projects, American Cockroach Droppings, Benjamin Wadsworth Height, Tp-link Archer Ax6000 Review, Advanced Calculus By Woods Pdf,